As 2026 begins, Java Burn reviews are once again climbing search results, not because of hype alone, but because ...
The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...
At the end of a seemingly ubiquitous commercial for telehealth company Ro, a characteristically flabbergasted Charles Barkley speaks for us all when he remarks, “Wait, you’re telling me they have a ...
Patients are turning to unregulated online pharmacies for cheaper versions of GLP-1 drugs. Attorney General William Tong said ...
Ro is a telehealth company that offers virtual consultations and prescriptions for various health concerns, including GLP-1 weight-loss medications. The Ro Body program includes a monthly membership ...
With millions of people using injectable GLP-1 medications like Ozempic, Wegovy or Zepbound, many may wonder what happens if they stop. Previous clinical trials suggested a discouraging "rebound" ...
A new class of weight-loss drug just took a major step toward approval for use. In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 ...
Cyndy Dowling struggled with her weight for decades until she found what she thought was a lifelong solution: a monthly injection of one of the popular new weight-loss drugs. The 69-year-old easily ...
Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. In early March the U.S. Food and Drug Administration sent a warning letter to Novo ...
While GLP-1 weight loss meds have been a mainstay in pop culture for a few years now, they're potentially about to get even more widespread. Formerly only available as an injection, Wegovy recently ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results